EE05075B1 - POL1212 aminohappejrjestust kodeeriv DNA, seda sisaldav ekspressioonivektor, sea modifitseeritud VIII-tegur, sellel p?hinev ravimkompositsioon ning meetod sea modifitseeritud VIII-teguri aminohappejrjestust omava valgu valmistamiseks - Google Patents
POL1212 aminohappejrjestust kodeeriv DNA, seda sisaldav ekspressioonivektor, sea modifitseeritud VIII-tegur, sellel p?hinev ravimkompositsioon ning meetod sea modifitseeritud VIII-teguri aminohappejrjestust omava valgu valmistamiseksInfo
- Publication number
- EE05075B1 EE05075B1 EEP200200510A EEP200200510A EE05075B1 EE 05075 B1 EE05075 B1 EE 05075B1 EE P200200510 A EEP200200510 A EE P200200510A EE P200200510 A EEP200200510 A EE P200200510A EE 05075 B1 EE05075 B1 EE 05075B1
- Authority
- EE
- Estonia
- Prior art keywords
- factor viii
- amino acid
- acid sequence
- porcine factor
- modified porcine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/10—Factor VIII, AHF; related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Glass Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fish Paste Products (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/523,656 US6458563B1 (en) | 1996-06-26 | 2000-03-10 | Modified factor VIII |
PCT/US2001/005076 WO2001068109A1 (en) | 2000-03-10 | 2001-02-16 | Modified factor viii |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200200510A EE200200510A (et) | 2004-02-16 |
EE05075B1 true EE05075B1 (et) | 2008-10-15 |
Family
ID=24085870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200200510A EE05075B1 (et) | 2000-03-10 | 2001-02-16 | POL1212 aminohappejrjestust kodeeriv DNA, seda sisaldav ekspressioonivektor, sea modifitseeritud VIII-tegur, sellel p?hinev ravimkompositsioon ning meetod sea modifitseeritud VIII-teguri aminohappejrjestust omava valgu valmistamiseks |
Country Status (36)
Country | Link |
---|---|
US (3) | US6458563B1 (no) |
EP (1) | EP1280540B1 (no) |
JP (1) | JP4044337B2 (no) |
KR (1) | KR100485525B1 (no) |
CN (1) | CN1191360C (no) |
AT (1) | ATE391512T1 (no) |
AU (2) | AU3841601A (no) |
BE (1) | BE2016C024I2 (no) |
BR (2) | BRPI0109131B8 (no) |
CA (1) | CA2400295C (no) |
CY (2) | CY1108179T1 (no) |
CZ (1) | CZ298250B6 (no) |
DE (1) | DE60133541T2 (no) |
DK (1) | DK1280540T3 (no) |
EE (1) | EE05075B1 (no) |
ES (1) | ES2304379T3 (no) |
FR (1) | FR16C0016I2 (no) |
HK (1) | HK1051004A1 (no) |
HU (2) | HU227804B1 (no) |
IL (2) | IL151371A0 (no) |
LT (1) | LTC1280540I2 (no) |
LU (1) | LU93049I2 (no) |
ME (1) | MEP8209A (no) |
MX (1) | MXPA02008798A (no) |
NL (1) | NL300808I2 (no) |
NO (2) | NO331935B1 (no) |
NZ (1) | NZ520799A (no) |
PL (1) | PL202936B1 (no) |
PT (1) | PT1280540E (no) |
RS (1) | RS50364B (no) |
RU (1) | RU2285724C2 (no) |
SI (1) | SI1280540T1 (no) |
SK (1) | SK286205B6 (no) |
UA (1) | UA75064C2 (no) |
WO (1) | WO2001068109A1 (no) |
ZA (1) | ZA200206810B (no) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7560107B2 (en) | 1996-06-26 | 2009-07-14 | Emory University | Modified factor VIII |
US7615622B2 (en) * | 2001-01-12 | 2009-11-10 | University Of Maryland, Baltimore | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII |
AU2002337901B2 (en) | 2001-10-05 | 2008-01-17 | Expression Therapeutics Llc | Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use |
MXPA04005079A (es) * | 2001-11-30 | 2004-08-19 | Univ Emory | Variantes del dominio c2 del factor viii. |
GB0207092D0 (en) * | 2002-03-26 | 2002-05-08 | Sod Conseils Rech Applic | Stable pharmaceutical composition containing factor VIII |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US7485291B2 (en) * | 2003-06-03 | 2009-02-03 | Cell Genesys, Inc. | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof |
WO2005017149A1 (en) * | 2003-06-03 | 2005-02-24 | Cell Genesys, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
WO2005000891A2 (en) * | 2003-06-26 | 2005-01-06 | Merck Patent Gmbh | Thrombopoietin proteins with improved properties |
US20050059023A1 (en) * | 2003-09-16 | 2005-03-17 | Cantor Thomas L. | Methods and kits for monitoring resistance to therapeutic agents |
US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
US7855274B2 (en) * | 2003-12-03 | 2010-12-21 | University Of Rochester | Recombinant factor VIII having increased specific activity |
EP1750733B1 (en) * | 2004-05-03 | 2013-12-11 | Emory University | METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII |
WO2005123928A1 (en) * | 2004-06-08 | 2005-12-29 | Battelle Memorial Institute | Production of human coagulation factor viii from plant cells and whole plants |
DK1824988T3 (en) * | 2004-11-12 | 2017-08-07 | Bayer Healthcare Llc | LOCATION-SPECIFIC MODIFICATION OF FVIII |
WO2006063031A2 (en) | 2004-12-06 | 2006-06-15 | Haplomics | Allelic variants of human factor viii |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
WO2007065691A2 (en) | 2005-12-07 | 2007-06-14 | Technische Universität München | Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins |
EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
JP2009533364A (ja) * | 2006-04-11 | 2009-09-17 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 治療用ポリペプチドのインビボでの回収を増大させる方法 |
US7939632B2 (en) * | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
KR101542752B1 (ko) | 2006-12-22 | 2015-08-10 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 변형된 응고 인자 |
EP1935430A1 (en) * | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
FR2913020B1 (fr) * | 2007-02-23 | 2012-11-23 | Biomethodes | Nouveaux facteurs viii pour le traitement des hemophiles de type a |
EP1988101A1 (en) | 2007-05-04 | 2008-11-05 | Novo Nordisk A/S | Improvement of factor VIII polypeptide titers in cell cultures |
US8183345B2 (en) * | 2007-11-01 | 2012-05-22 | University Of Rochester | Recombinant factor VIII having reduced inactivation by activated protein C |
EP2149603A1 (en) | 2008-07-28 | 2010-02-03 | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH | Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders |
DK3178835T3 (da) | 2009-02-03 | 2019-06-24 | Amunix Pharmaceuticals Inc | Forlængede rekombinante polypeptider og sammensætninger omfattende samme |
US20110046060A1 (en) | 2009-08-24 | 2011-02-24 | Amunix Operating, Inc., | Coagulation factor IX compositions and methods of making and using same |
DK2440239T3 (en) | 2009-06-09 | 2017-10-16 | Prolong Pharmaceuticals Llc | HEMOGLOBIN FORMATIONS |
US20130116182A1 (en) * | 2009-11-13 | 2013-05-09 | Kathleen Pratt | Factor VIII B Cell Epitope Variants Having Reduced Immunogenicity |
JP5903048B2 (ja) | 2009-12-06 | 2016-04-13 | バイオジェン ヘモフィリア インコーポレイテッド | 第VIII−Fc因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
WO2011088391A2 (en) * | 2010-01-14 | 2011-07-21 | Haplomics, Inc. | Predicting and reducing alloimmunogenicity of protein therapeutics |
SG186875A1 (en) | 2010-07-09 | 2013-02-28 | Biogen Idec Hemophilia Inc | Chimeric clotting factors |
EP2591101B1 (en) | 2010-07-09 | 2018-11-07 | Bioverativ Therapeutics Inc. | Systems for factor viii processing and methods thereof |
BR112013011041B1 (pt) | 2010-11-05 | 2021-05-25 | Baxalta GmbH | variante de fator viii, método para produzir uma variante de fviii, uso da variante de fator viii, e, composição farmacêutica |
EA201370151A1 (ru) * | 2011-01-05 | 2013-11-29 | Экспрешен Терапетикс, Ллс | Высокопродуктивная суспензионная клеточная линия, система и способ ее получения |
EP3527218A1 (en) | 2011-06-10 | 2019-08-21 | Bioverativ Therapeutics Inc. | Pro-coagulant compounds and methods of use thereof |
PT3513804T (pt) | 2011-07-08 | 2022-06-02 | Bioverativ Therapeutics Inc | Polipéptidos fator viii híbridos e quiméricos, e métodos de utilização dos mesmos |
US10656167B2 (en) | 2011-07-25 | 2020-05-19 | Bioverativ Therapeutics Inc. | Assays to monitor bleeding disorders |
CN102277379B (zh) * | 2011-08-18 | 2013-07-24 | 中国科学院遗传与发育生物学研究所 | 表达凝血因子viii的表达载体及其应用 |
CA2863329C (en) | 2012-01-12 | 2023-01-03 | Biogen Idec Ma Inc. | Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy |
PL2804623T3 (pl) | 2012-01-12 | 2020-03-31 | Bioverativ Therapeutics Inc. | Chimeryczne polipeptydy czynnika viii i ich zastosowania |
AU2013204636B2 (en) | 2012-02-15 | 2016-04-14 | Bioverativ Therapeutics Inc. | Recombinant Factor VIII proteins |
BR112014020694A2 (pt) | 2012-02-15 | 2018-05-08 | Amunix Operating Inc. | proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a |
EP2666782A1 (en) * | 2012-05-22 | 2013-11-27 | Imnate Sarl | Coagulation factor VIII with reduced immunogenicity. |
CN104427995A (zh) | 2012-06-08 | 2015-03-18 | 比奥根艾迪克Ma公司 | 嵌合凝血因子 |
CN104519897A (zh) | 2012-06-08 | 2015-04-15 | 比奥根艾迪克Ma公司 | 促凝血化合物 |
EP3404105A1 (en) | 2012-07-06 | 2018-11-21 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
EA029685B1 (ru) | 2012-07-11 | 2018-04-30 | Амуникс Оперэйтинг Инк. | Комплекс фактора viii с xten и белком фактора фон виллебранда и его применение (варианты) |
EP2877202A4 (en) | 2012-07-25 | 2016-06-01 | Biogen Ma Inc | BLOOD FACTOR MONITORING TEST AND USES THEREOF |
AU2013331000B2 (en) | 2012-10-18 | 2018-04-19 | Bioverativ Therapeutics Inc. | Methods of using a fixed dose of a clotting factor |
EP3943102A1 (en) | 2012-10-30 | 2022-01-26 | Bioverativ Therapeutics Inc. | Methods of using fviii polypeptide |
EP2928303A4 (en) | 2012-12-07 | 2016-07-13 | Haplomics Inc | FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION |
HUE063051T2 (hu) | 2013-02-15 | 2023-12-28 | Bioverativ Therapeutics Inc | Optimalizált VIII. faktor gén |
TWI629993B (zh) | 2013-03-15 | 2018-07-21 | 美商生物化學醫療公司 | 因子viii多肽調配物 |
SG10201707600XA (en) | 2013-03-15 | 2017-11-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
JP2016523919A (ja) | 2013-06-28 | 2016-08-12 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Xtenを有するトロンビン切断可能リンカー及びその使用 |
EP3875106A1 (en) | 2013-08-08 | 2021-09-08 | Bioverativ Therapeutics Inc. | Purification of chimeric fviii molecules |
TWI667255B (zh) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子viii-xten融合物及其用途 |
EA201690817A1 (ru) | 2013-10-22 | 2016-08-31 | Дбв Текнолоджиз | Способ лечения гемофилии индукцией толерантности к факторам крови |
EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
EP4332839A3 (en) | 2013-12-06 | 2024-06-05 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
EP2881463A1 (en) | 2013-12-09 | 2015-06-10 | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH | Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders |
RS63583B1 (sr) | 2014-01-10 | 2022-10-31 | Bioverativ Therapeutics Inc | Himerni proteini faktora viii i njihova upotreba |
AU2015214245B2 (en) | 2014-02-04 | 2020-09-10 | Biogen Ma Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
US20170051041A1 (en) * | 2014-02-19 | 2017-02-23 | Kathleen Pratt | Factor viii b cell epitope variants having reduced immunogenicity |
WO2015132724A1 (en) | 2014-03-05 | 2015-09-11 | Pfizer Inc. | Improved muteins of clotting factor viii |
MA40864A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
TWI741992B (zh) | 2015-08-03 | 2021-10-11 | 美商百歐維拉提夫治療公司 | 因子ix融合蛋白以及其製備及使用方法 |
PE20231949A1 (es) * | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
CN116479001A (zh) | 2015-11-13 | 2023-07-25 | 武田药品工业株式会社 | 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体 |
EP3374388A1 (en) | 2015-11-13 | 2018-09-19 | Baxalta Incorporated | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
BR112018015659A2 (pt) | 2016-02-01 | 2018-12-26 | Bioverativ Therapeutics Inc | genes otimizados do fator viii |
CN109790529A (zh) | 2016-06-24 | 2019-05-21 | 财团法人牧岩生命科学研究所 | 包含FVIII和vWF因子的嵌合蛋白及其用途 |
US20190381149A1 (en) | 2016-12-02 | 2019-12-19 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
AU2017368328A1 (en) | 2016-12-02 | 2019-07-18 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
CN111108196A (zh) * | 2017-05-09 | 2020-05-05 | 爱莫里大学 | 凝血因子变体及其用途 |
AU2018313921A1 (en) | 2017-08-09 | 2020-03-12 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof |
MX2020008152A (es) | 2018-02-01 | 2020-11-24 | Bioverativ Therapeutics Inc | Uso de vectores lentivirales que expresan el factor viii. |
RU2020136050A (ru) | 2018-04-04 | 2022-05-06 | Сайджилон Терапьютикс, Инк. | Имплантируемые частицы и соответствующие способы |
MX2020012397A (es) | 2018-05-18 | 2021-04-12 | Bioverativ Therapeutics Inc | Metodos de tratamiento de la hemofilia a. |
TW202006141A (zh) | 2018-07-16 | 2020-02-01 | 美商巴克斯歐塔公司 | 使用編碼具有增加表現的重組fviii變異體之病毒載體的a型血友病之基因療法 |
WO2020033863A1 (en) | 2018-08-09 | 2020-02-13 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
UY38389A (es) | 2018-09-27 | 2020-04-30 | Sigilon Therapeutics Inc | Dispositivos implantables para terapia celular y métodos relacionados |
IL284648B1 (en) | 2019-01-16 | 2024-08-01 | Baxalta Incorporated | Viral vectors encoding recombinant FVIII variants with enhanced expression for hemophilia A gene therapy |
US20220233650A1 (en) | 2019-06-19 | 2022-07-28 | Bioverativ Therapeutics Inc. | Recombinant factor viii-fc for treating hemophilia and low bone mineral density |
US20200405883A1 (en) | 2019-06-20 | 2020-12-31 | Baxalta Incorporated | Method of treatment with viral-based gene therapy |
WO2021119357A2 (en) | 2019-12-12 | 2021-06-17 | Baxalta Incorporated | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
TW202246505A (zh) * | 2021-03-05 | 2022-12-01 | 俄羅斯聯邦商亞那拜恩有限公司 | 編碼凝血因子ix蛋白的密碼子優化的核酸及其用途 |
WO2022212162A1 (en) * | 2021-03-31 | 2022-10-06 | Haemonetics Corporation | Hemostasis measurement device quality control formulations |
EP4355768A1 (en) | 2021-06-14 | 2024-04-24 | Takeda Pharmaceutical Company Limited | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
AR126846A1 (es) | 2021-08-23 | 2023-11-22 | Bioverativ Therapeutics Inc | Genes del factor viii optimizados |
CN118019758A (zh) | 2021-09-30 | 2024-05-10 | 比奥维拉迪维治疗股份有限公司 | 编码免疫原性降低的因子viii多肽的核酸 |
WO2024081309A1 (en) | 2022-10-11 | 2024-04-18 | Sigilon Therapeutics, Inc. | Engineered cells and implantable elements for treatment of disease |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
EP0182448A3 (en) | 1984-08-24 | 1987-10-28 | Genetics Institute, Inc. | Production of factor viii and related products |
ES8801674A1 (es) * | 1985-04-12 | 1988-02-16 | Genetics Inst | Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante. |
JPH0387173A (ja) | 1987-09-10 | 1991-04-11 | Teijin Ltd | ヒト活性化天然型ファクター8cの製造方法及びそれに用いる形質転換体 |
DK162233C (da) | 1989-11-09 | 1992-03-16 | Novo Nordisk As | Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii |
US5663060A (en) | 1992-04-07 | 1997-09-02 | Emory University | Hybrid human/animal factor VIII |
US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
US6180371B1 (en) * | 1996-06-26 | 2001-01-30 | Emory University | Modified factor VIII |
US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
AU6291896A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains |
AU6455896A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
WO2002024723A1 (en) * | 2000-09-19 | 2002-03-28 | Emory University | Modified factor viii |
MXPA04005079A (es) * | 2001-11-30 | 2004-08-19 | Univ Emory | Variantes del dominio c2 del factor viii. |
US7105745B2 (en) * | 2002-12-31 | 2006-09-12 | Thomas & Betts International, Inc. | Water resistant electrical floor box cover assembly |
-
2000
- 2000-03-10 US US09/523,656 patent/US6458563B1/en not_active Expired - Lifetime
-
2001
- 2001-02-16 PT PT01910853T patent/PT1280540E/pt unknown
- 2001-02-16 DE DE60133541T patent/DE60133541T2/de not_active Expired - Lifetime
- 2001-02-16 CZ CZ20023346A patent/CZ298250B6/cs unknown
- 2001-02-16 PL PL359672A patent/PL202936B1/pl unknown
- 2001-02-16 WO PCT/US2001/005076 patent/WO2001068109A1/en active IP Right Grant
- 2001-02-16 HU HU0300586A patent/HU227804B1/hu active Protection Beyond IP Right Term
- 2001-02-16 BR BRPI0109131A patent/BRPI0109131B8/pt not_active IP Right Cessation
- 2001-02-16 BR BR122013026957A patent/BR122013026957A8/pt not_active Application Discontinuation
- 2001-02-16 NZ NZ520799A patent/NZ520799A/en not_active IP Right Cessation
- 2001-02-16 AU AU3841601A patent/AU3841601A/xx active Pending
- 2001-02-16 EE EEP200200510A patent/EE05075B1/xx active Protection Beyond IP Right Term
- 2001-02-16 MX MXPA02008798A patent/MXPA02008798A/es active IP Right Grant
- 2001-02-16 AT AT01910853T patent/ATE391512T1/de active
- 2001-02-16 SK SK1439-2002A patent/SK286205B6/sk not_active IP Right Cessation
- 2001-02-16 RS YUP-680/02A patent/RS50364B/sr unknown
- 2001-02-16 SI SI200130823T patent/SI1280540T1/sl unknown
- 2001-02-16 ES ES01910853T patent/ES2304379T3/es not_active Expired - Lifetime
- 2001-02-16 DK DK01910853T patent/DK1280540T3/da active
- 2001-02-16 JP JP2001566673A patent/JP4044337B2/ja not_active Expired - Lifetime
- 2001-02-16 AU AU2001238416A patent/AU2001238416B2/en active Active
- 2001-02-16 CA CA2400295A patent/CA2400295C/en not_active Expired - Lifetime
- 2001-02-16 ME MEP-82/09A patent/MEP8209A/xx unknown
- 2001-02-16 KR KR10-2002-7011843A patent/KR100485525B1/ko active IP Right Grant
- 2001-02-16 IL IL15137101A patent/IL151371A0/xx unknown
- 2001-02-16 RU RU2002124123/13A patent/RU2285724C2/ru active
- 2001-02-16 UA UA2002097145A patent/UA75064C2/uk unknown
- 2001-02-16 CN CNB018063179A patent/CN1191360C/zh not_active Expired - Lifetime
- 2001-02-16 EP EP01910853A patent/EP1280540B1/en not_active Expired - Lifetime
-
2002
- 2002-06-28 US US10/187,319 patent/US7012132B2/en not_active Expired - Fee Related
- 2002-08-21 IL IL151371A patent/IL151371A/en active IP Right Grant
- 2002-08-26 ZA ZA200206810A patent/ZA200206810B/en unknown
- 2002-09-09 NO NO20024296A patent/NO331935B1/no not_active IP Right Cessation
-
2003
- 2003-05-06 HK HK03103224A patent/HK1051004A1/xx not_active IP Right Cessation
-
2004
- 2004-09-10 US US10/938,414 patent/US7122634B2/en not_active Expired - Fee Related
-
2008
- 2008-07-07 CY CY20081100709T patent/CY1108179T1/el unknown
-
2016
- 2016-04-27 LU LU93049C patent/LU93049I2/xx unknown
- 2016-04-29 FR FR16C0016C patent/FR16C0016I2/fr active Active
- 2016-05-02 BE BE2016C024C patent/BE2016C024I2/fr unknown
- 2016-05-06 LT LTPA2016014C patent/LTC1280540I2/lt unknown
- 2016-05-09 NL NL300808C patent/NL300808I2/nl unknown
- 2016-05-09 HU HUS1600020C patent/HUS1600020I1/hu unknown
- 2016-05-10 NO NO2016007C patent/NO2016007I2/no unknown
- 2016-05-10 CY CY2016011C patent/CY2016011I2/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE05075B1 (et) | POL1212 aminohappejrjestust kodeeriv DNA, seda sisaldav ekspressioonivektor, sea modifitseeritud VIII-tegur, sellel p?hinev ravimkompositsioon ning meetod sea modifitseeritud VIII-teguri aminohappejrjestust omava valgu valmistamiseks | |
PT1200105E (pt) | Factor viii modificado | |
BR9814276A (pt) | Antìgenos de superfìcie | |
DE60032486D1 (de) | Prion protein peptide und deren verwendung | |
ATE485371T1 (de) | Varianten des menschlichen koagulationsfaktors vii | |
ATE312176T1 (de) | Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien | |
DK1368060T3 (da) | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme | |
DE69935078D1 (de) | Eine mutante phospholamban moleküle und deren verwendung zur behandlung von herzkrankheiten und herzversagen | |
DE69433243D1 (de) | Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit | |
ATE313628T1 (de) | Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen | |
DE60041985D1 (de) | Zusammensetzungen und verfahren zur erfassung von stress induzierten proteinen | |
ATE512981T1 (de) | Identifizierung von ses-3 (spr-5) aus c. elegans sowie dessen verwendungen | |
ATE364081T1 (de) | Identifizierung von ses-1 aus c. elegans sowie dessen verwendung | |
DE50000562D1 (de) | Mittel zur behandlung von pigmentierungsstörungen | |
AR002956A1 (es) | Proteinas utiles para el tratamiento de la obesidad y de trastornos relacionados con ella, proceso para obtenerlas y composiciones farmaceuticasque las contienen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |
|
AA1Y | Spc filed |
Free format text: PRODUCT NAME: SUSOKTOKOG ALFA;REG NO/DATE: EU/1/15/1035 13.11.2015 Spc suppl protection certif: C20160010 Filing date: 20160509 |
|
HE1A | Change of address | ||
FG1Y | Spc granted |
Free format text: PRODUCT NAME: SUSOKTOKOG ALFA;REG NO/DATE: EU/1/15/1035 13.11.2015 Spc suppl protection certif: C20160010 00183 Filing date: 20160509 Extension date: 20260216 |